Latanoprost/Timolol Upjohn

Latanoprost and Timolol, the active ingredients in Latanoprost/Timolol Upjohn, are a prostaglandin analog and a beta‑blocker presented as an ophthalmic solution for ocular use. It treats open‑angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Latanoprost/Timolol Upjohn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost/Timolol is indicated for conditions affecting intraocular pressure within the glaucoma disease family. - Open‑angle glaucoma: lowers intraocular pressure to prevent optic‑nerve damage. - Ocular hypertension: reduces elevated eye pressure to normal levels. - Primary open‑angle glaucoma: maintains target pressure to preserve visual field.

Latanoprost/Timolol may cause ocular and systemic reactions.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Conjunctival hyperemia (red eye). - Eyelash growth or darkening. - Mild headache.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., swelling, rash). - Significant decrease in heart rate or bronchospasm in susceptible individuals. - Persistent eye pain or vision loss. - Periorbital fat atrophy with long‑term use.

Before using Latanoprost/Timolol, consider the following safety measures. - Cardiovascular disease: assess heart rate and blood pressure. - Respiratory conditions: avoid in patients with asthma or COPD. - Pregnancy and lactation: use only if benefit outweighs risk. - Contact lens wearers: remove lenses before instillation and wait 15 minutes before reinserting. - Concomitant ocular surgery: discontinue prior to procedure as advised by surgeon. Store at below 25°C: keep in the original container, protect from light and moisture.

Latanoprost/Timolol can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Non‑selective beta‑blockers (systemic): may cause additive bradycardia or bronchospasm. - MAO inhibitors: can enhance ocular hypotensive effect.

Moderate Interactions (Monitor Closely): - Other intraocular pressure‑lowering agents: may increase risk of excessive pressure reduction. - Anticholinergic eye drops: could diminish therapeutic effect. - Systemic antihypertensives: monitor blood pressure for additive lowering.